RESEARCH - IV Boniva effective for postmenopausal osteoporosis

[Guest guest]

Intravenous ibandronate effective for postmenopausal osteoporosis

6/20/2006

By: Reuters Health

NEW YORK (Reuters Health), Jun 20 - Intravenous ibandronate, given every two

or three months, is effective in postmenopausal women with osteoporosis and

possibly more effective than daily oral dosage, according to a report in the

June issue of Arthritis & Rheumatism.

Oral bisphosphonates have proven effective for postmenopausal women with

osteoporosis, the authors explain, but some women are unable for various

reasons to tolerate oral dosing.

Dr. Pierre D. Delmas from Universite Claude Bernard Lyon, France, and

colleagues compared the efficacy and safety ibandronate in 1395

postmenopausal women randomized to intravenous ibandronate (given every two

or three months) or daily oral administration of this agent.

Bone mineral density (BMD) of the lumbar spine increased with all

treatments, the authors report, with the greatest increases seen in the

intravenous treatment groups. The BMD results were similar for the proximal

femur.

Significantly more patients in the two-month and three-month intravenous

treatment groups achieved BMD values equal to or greater to baseline values

than did patients in the oral treatment group, for both lumbar spine and

total hip, the results indicate.

There were pronounced decreases from baseline in serum C-telopeptide of type

1 collagen (CTX) with all administration schedules, the researchers note,

and the decreases did not differ significantly between oral and intravenous

groups.

By the end of the 12-month study, the three treatment groups did not differ

significantly in the incidence of all adverse events, treatment-related

adverse events, or treatment-related adverse events that led to study

withdrawal, the report indicates.

None of the 244 patients who underwent ECG examinations had ibandronate

treatment-related changes in heart rate, atrioventricular conduction,

cardiac depolarization, or QT interval, the investigators report.

The study findings " indicate that intravenous ibandronate injections

administered every two months or every three months are at least as

effective and similarly well tolerated as an established regimen of daily

oral ibandronate in postmenopausal women with osteoporosis, " the authors

conclude.

Intravenous ibandronate will probably be advantageous for patients who

cannot tolerate oral bisphosphonates or have difficulty with treatment

compliance, the researchers added. They are planning to continue the study

for another year and then re-evaluate the patients.

Last Updated: 2006-06-20 10:17:49 -0400 (Reuters Health)

Arthritis Rheum 2006;54:1838-1846.

http://www.auntminnie.com/index.asp?Sec=sup & Sub=ort & Pag=dis & ItemId=71452

Not an MD

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org

[Guest guest]

Hi ,

This is so funny that you sent this information. I am calling Boniva

tomorrow to find out more about the Iv Boniva. I am hesitant to start this

drug and want to make sure I am doing the right thing. Thanks for sending

this out. I am printing it and taking it to the doctors.

Hope you are doing good.

Lynn

[ ] RESEARCH - IV Boniva effective for postmenopausal

osteoporosis

> Intravenous ibandronate effective for postmenopausal osteoporosis

>

> 6/20/2006

> By: Reuters Health

>

> NEW YORK (Reuters Health), Jun 20 - Intravenous ibandronate, given every

> two

> or three months, is effective in postmenopausal women with osteoporosis

> and

> possibly more effective than daily oral dosage, according to a report in

> the

> June issue of Arthritis & Rheumatism.

> Oral bisphosphonates have proven effective for postmenopausal women with

> osteoporosis, the authors explain, but some women are unable for various

> reasons to tolerate oral dosing.

>

> Dr. Pierre D. Delmas from Universite Claude Bernard Lyon, France, and

> colleagues compared the efficacy and safety ibandronate in 1395

> postmenopausal women randomized to intravenous ibandronate (given every

> two

> or three months) or daily oral administration of this agent.

>

> Bone mineral density (BMD) of the lumbar spine increased with all

> treatments, the authors report, with the greatest increases seen in the

> intravenous treatment groups. The BMD results were similar for the

> proximal

> femur.

>

> Significantly more patients in the two-month and three-month intravenous

> treatment groups achieved BMD values equal to or greater to baseline

> values

> than did patients in the oral treatment group, for both lumbar spine and

> total hip, the results indicate.

>

> There were pronounced decreases from baseline in serum C-telopeptide of

> type

> 1 collagen (CTX) with all administration schedules, the researchers note,

> and the decreases did not differ significantly between oral and

> intravenous

> groups.

>

> By the end of the 12-month study, the three treatment groups did not

> differ

> significantly in the incidence of all adverse events, treatment-related

> adverse events, or treatment-related adverse events that led to study

> withdrawal, the report indicates.

>

> None of the 244 patients who underwent ECG examinations had ibandronate

> treatment-related changes in heart rate, atrioventricular conduction,

> cardiac depolarization, or QT interval, the investigators report.

>

> The study findings " indicate that intravenous ibandronate injections

> administered every two months or every three months are at least as

> effective and similarly well tolerated as an established regimen of daily

> oral ibandronate in postmenopausal women with osteoporosis, " the authors

> conclude.

>

> Intravenous ibandronate will probably be advantageous for patients who

> cannot tolerate oral bisphosphonates or have difficulty with treatment

> compliance, the researchers added. They are planning to continue the study

> for another year and then re-evaluate the patients.

>

> Last Updated: 2006-06-20 10:17:49 -0400 (Reuters Health)

>

> Arthritis Rheum 2006;54:1838-1846.

>

> http://www.auntminnie.com/index.asp?Sec=sup & Sub=ort & Pag=dis & ItemId=71452

>

>

>

>

> Not an MD

>

> I'll tell you where to go!

>

> Mayo Clinic in Rochester

> http://www.mayoclinic.org/rochester

>

> s Hopkins Medicine

> http://www.hopkinsmedicine.org

>

>

>

>

>